News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Pharmaxis.
RELATED STOCKHEAD STORIES
Health & Biotech
ScoPo’s Powerplays: Investors look to Healthcare for ESG exposure, and Volpara is the poster child
Health & Biotech
ASX Health Stocks: Amplia eyes human trials for pancreatic cancer drug
News
Closing Bell: ASX edges lower, but hydrogen stocks rip higher
News
ASX Small Cap Lunch Wrap: Who’s up for a new ETF today?
Health & Biotech
ASX Health Stocks: Pharmaxis jumps 9pc on FDA approval
Health & Biotech
Check Up: Rhythm plans TGA submission and pig tissue MOU fails to impress
Health & Biotech
ASX Health Stocks: Pharmaxis progresses to Phase 2 study on bone marrow cancer
Health & Biotech
Check Up: Dimerix and ImpediMed announced breakthroughs, while earnings dominate news flow in August
Health & Biotech
ASX Health Stocks: Beamtree gets on the M&A trail while Creso Pharma eyes NASDAQ listing
Health & Biotech
ScoPo’s Powerplays: Quality names continue to catch a bid as earnings roll in
Health & Biotech
ASX Health Stocks: Osprey jumps 8% on solid first half; Bard1 concludes successful study
News
Market highlights and 5 ASX small caps to watch on Tuesday
Health & Biotech
ASX health stocks: dorsaVi leads the pack with 12% jump on major contract extension
News
Market Highlights and 5 ASX Small Caps to watch on Thursday
Health & Biotech
ScoPo’s Powerplays: ‘Go long equities’ as Nanosonics, Antisense, Volpara to benefit from V-shaped recovery
News
Last Orders: ASX begins FY22 down 0.65 per cent
Health & Biotech
